SCHEMBL4886969

SCHEMBL4886969

CC(=O)N1CCN(C(=O)CCC(=O)Nc2ccc(Cl)cc2C(=O)N2C[C@H](C)C[C@H](C)C2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 3/20 0.48
GAA P10253 1/20 0.48
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 2/20 0.41
SERPINE1 P05121 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
TP53 P04637 2/20 0.40
MEN1 O00255 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CCKBR P32239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896054 0.92 LMNA (0.48) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL4896941 0.89 ALDH1A1 (0.47) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL4892109 0.89 LMNA (0.45) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL4894751 0.88 POLB (0.43) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL14087736 0.86 SMN1; SMN2 (0.50) SMN1; SMN2LMNAALDH1A1NPSR1MAPK1
SCHEMBL4895411 0.83 ALDH1A1 (0.45) SMN1; SMN2LMNAALDH1A1NPSR1KMT2A
SCHEMBL14102807 0.83 F2 (0.40) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL4886249 0.82 POLB (0.41) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL4894181 0.81 ALDH1A1 (0.46) SMN1; SMN2LMNAALDH1A1NPSR1TSHR
SCHEMBL4887023 0.81 GABRP (0.51) SMN1; SMN2LMNAMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200512-A1 Hepatitis C virus polymerase inhibitors SSU72, POLR2H, POLR2E SMN1; SMN2 4735/4885LMNA 3432/4885MAPT 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.